ObjectiveTo explore the clinical effect of half dose HAG/CAG/IAG regimen combined with azacitidine on patients with acute myeloid leukemia (AML). MethodsA total of 150 patients with AML admitted to our hospital from December 2019 to December 2020 were selected as the research objects, and they were randomly divided into observation group and control group, with 75 cases in each group. The control group was treated with standard dose HAG/CAG/IAG regimen, while the observation group was treated with half dose HAG/CAG/IAG regimen combined with azacitidine, for 2 courses of continuous treatment. The clinical efficacy was compared between two groups. The immune function and peripheral blood cell levels of the two groups were detected and compared before and after treatment. The occurrence of non-hematologic adverse events during treatment and the 1-year survival rate after treatment were compared between the two groups. ResultsWith 2 courses of treatment, the total effective rate of treatment of the observation group (92.0%) was significantly higher than that of the control group (80.0%), with a statistically significant difference (P＜0.05). Before treatment, there were no statistically significant differences in the levels of neutrophil count, hemoglobin (Hb) and platelet count (PLT) between the two groups (P＞0.05). After 2 courses of treatment, the levels of neutrophil count, Hb and PLT in the two groups increased significantly, which were higher in the observation group than those in the control group, with statistically significant differences (P＜0.05). Before treatment, there were no statistically significant differences in the levels of CD3+, CD4+, and CD4+ /CD8+ between the two groups (P＞0.05). After 2 courses of treatment, the levels of CD3+, CD4+ and CD4+/CD8+ in both groups decreased significantly, which were higher in the observation group than those in the control group, with statistically significant differences (P＜0.05). During treatment, the occurrence of non-hematologic adverse events in the observation group (6.67%) was significantly lower than that in the control group (17.33%), with a statistically significant difference (P＜0.05). After treatment, the 1-year survival rate of the observation group (92.0%) was higher than that of the control group (85.3%), while the difference was not statistically significant (P＞0.05). ConclusionHalf dose HAG/CAG/IAG regimen combined with azacitidine is obviously effective in the treatment of patients with acute myeloid leukemia, which can significantly improve the hematopoietic function of patients, with less damage to the immune function of patients and high therapeutic safety.

无